尿液pH-铵酸碱评分与CKD进展
本研究基于三个CKD 3-4期队列(N=82、58、73)开发了由尿pH和铵浓度计算的尿液酸碱评分,定义低于健康对照95%预测区间下限为亚临床酸中毒。亚临床酸中毒在各队列中约占67%,与18个月实测GFR下降增大18%及CKD进展风险显著升高相关,且预测价值优于单用铵排泄。
要点
- 尿液酸碱评分可识别CKD 3-4期患者的亚临床酸中毒。
- 亚临床酸中毒与18个月实测GFR下降增大18%相关。
- 该评分对CKD进展的预测价值优于单用尿铵排泄。
核心结论
- 基于尿pH和铵的酸碱评分所定义的亚临床酸中毒与CKD 3-4期患者CKD进展风险升高相关。
研究设计与样本
- 尿液酸碱评分由尿pH和尿铵浓度推导计算,亚临床酸中毒定义为评分低于健康对照95%预测区间下限。
- 主要结局为18个月实测GFR变化和随访至10年的CKD进展(eGFR下降≥50%、启动长期透析或肾移植)。
主要发现
- 亚临床酸中毒在各队列中均常见,分别为54/82、48/73和40/58,约67%。
- 亚临床酸中毒与18个月实测GFR下降增大18%(95%CI 2-32)相关。
- 中位随访6年,亚临床酸中毒与CKD进展风险升高相关,开发队列调整HR为9.88(95%CI 1.27-76.7),验证队列为11.1(95%CI 2.88-42.5)。
- 酸碱评分对CKD进展的预测价值高于单用铵排泄。
关键数值与推荐
- 亚临床酸中毒定义为尿液酸碱评分低于健康对照95%预测区间下限。
- CKD进展定义为eGFR下降≥50%、启动长期透析或肾移植。
临床怎么用
- 尿液酸碱评分或可用于CKD 3-4期患者亚临床酸中毒的识别和CKD进展风险分层。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: This study developed a urine acid/base score to assess tubular acid excretion capacity and identify early acid retention in CKD. The results show that early signs of acid retention (a low acid/base score) are associated with a higher risk for CKD progression. Future research should address if a low urine acid/base score can be improved and if this translates into clinically meaningful effects. BACKGROUND: Acidosis is associated with exacerbated loss of kidney function in CKD. Currently, acid/base status is assessed by plasma measures, although organ-damaging covert acidosis, subclinical acidosis, may be present before reflected in plasma. Low urine NH4+ excretion associates with poor kidney outcomes in CKD and is proposed as a marker for subclinical acidosis. However, low NH4+ excretion could result from either a low capacity or a low demand for acid excretion. We hypothesized that a urine acid/base score reflecting both the demand and capacity for acid excretion would better predict CKD progression. METHODS: Twenty-four–hour urine collections were included from three clinical studies of patients with CKD stage 3 and 4: a development cohort (N=82), a variation cohort (N=58), and a validation cohort (N=73). A urine acid/base score was derived and calculated from urinary pH and [NH4+]. Subclinical acidosis was defined as an acid/base score below the lower limit of the 95% prediction interval of healthy controls. The main outcomes were change in measured GFR after 18 months and CKD progression (defined as ≥50% decline in eGFR, initiation of long-term dialysis, or kidney transplantation) during up to 10 years of follow-up. RESULTS: Subclinical acidosis was prevalent in all cohorts (n=54/82, 48/73, and 40/58, respectively, approximately 67%). Subclinical acidosis was associated with an 18% (95% confidence interval [CI], 2 to 32) larger decrease of measured GFR after 18 months. During a median follow-up of 6 years, subclinical acidosis was associated with a higher risk of CKD progression. Adjusted hazard ratios were 9.88 (95% CI, 1.27 to 76.7) in the development cohort and 11.1 (95% CI, 2.88 to 42.5) in the validation cohort. The acid/base score had a higher predictive value for CKD progression than NH4+ excretion alone. CONCLUSIONS: Subclinical acidosis, defined by a new urine acid/base score, was associated with a higher risk of CKD progression in patients with CKD stage 3 and 4.
引用
- Svendsen SL, Rousing AQ, Carlsen RK, et al. A Urine pH-Ammonium Acid/Base Score and CKD Progression. J Am Soc Nephrol. 2024. PMID: 39485702. doi:10.1681/ASN.0000000000000447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。